

WOAH Reference Laboratory Reports Activities 2025

This report has been submitted: 18 février 2026 17:42

LABORATORY INFORMATION

*Name of disease (or topic) for which you are a designated WOA Reference Laboratory:	Lumpy skin disease
*Address of laboratory:	Groeselenberg 99, 1180 Uccle
*Tel:	+3223790627
*E-mail address:	nick.deregge@sciensano.be
Website:	https://www.sciensano.be/en
*Name (including Title) of Head of Laboratory (Responsible Official):	Prof. Nick De Regge; head of the service Exotic and vector-borne diseases
*Name (including Title and Position) of WOA Reference Expert:	Prof. Nick De Regge; head of the service Exotic and vector-borne diseases
*Which of the following defines your laboratory? Check all that apply:	Governmental

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOA Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests			
ELISA	Yes	10	30
virus neutralization test	Yes	0	30
Direct diagnostic tests			
realtime PCR	Yes	10	20
virus isolation	Yes	0	3

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOA?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOA Members?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient WOA Member Countries	Country of recipients
inactivated LSDV	PCR	inhouse	0ml	1ml	1	SERBIA,

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOAHA Members?

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOAHA Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

9. Did your laboratory validate vaccines according to WOAHA Standards for the designated pathogen or disease?

TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOAHA Members?

Yes

Name of WOAHA Member Country seeking assistance	Date	Which diagnostic test used	No. samples received for provision of diagnostic support	No. samples received for provision of confirmatory diagnoses
FRANCE	2025-07-31	PCR, sequencing	0	5
ITALY	2025-07-01	PCR, sequencing	0	5
SPAIN	2025-12-10	PCR, sequencing	0	10
SWITZERLAND	2025-07-10	ELISA, VNT, IPMA	30	0
NIGERIA	2025-01-09	PCR, sequencing	50	0

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOAHA Member?

Yes

Name of the WOAHA Member Country receiving a technical consultancy	Purpose	How the advice was provided
JAPAN	LSDV presence in meat	video-meeting
PAKISTAN	LSDV strain responsible for outbreak	emailing, sample exchange
INDIA	LSDV phylogeny	online meeting

TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOAHA Members other than the own?

Yes

Title of the study	Duration	Purpose of the study	Partners (Institutions)	WOAHA Member Countries involved other than your country
characterisation LSDV strains in Nigeria	1 year	characterise LSDV strains nigeria	Sciensano, Nigeria	NIGERIA
LSDV IGRA	6 months	evaluat LSDV IGRA for PVM	IVI	SWITZERLAND

13. In exercising your activities, have you identified any regulatory research needs* relevant for WOAHA?

Yes

Research need : 1

Please type the Research need: DIVA vaccine and diagnostics for LSDV

Relevance for WOAHA Disease Control, Standard Setting, Facilitation of international collaboration,

Relevance for the Code or Manual Code, Manual,

Field Vaccines,

Animal Category Terrestrial,

Disease:

Kind of disease (Zoonosis, Transboundary diseases) Transboundary diseases,

If any, please specify relevance for Codes or Manual, chapter and title

(e.g. Terrestrial Manual Chapter 2.3.5 - Minimum requirements for aseptic production in vaccine manufacture)

Answer:

Notes:

Answer:

TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

Yes

If the answer is yes, please provide details of the data collected:

whole genome sequencing of outbreak strains in Europe

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

Yes

If the answer is yes, please provide details of the data collected:

whole genome sequence of outbreak strains in Europe shared with country and european commission

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

5

b) International conferences:

14

c) National conferences:

0

d) Other (Provide website address or link to appropriate information):

TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOAHA Members?

Yes

a) Technical visit : 1

b) Seminars : 2

c) Hands-on training courses: 3

Nick De Regge - -

d) Internships (>1 month) 0

Type of technical training provided (a, b, c or d)	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
A	KOREA (REP. OF)	4
C	ETHIOPIA	1
C	ETHIOPIA	2
C	ALGERIA	1
B	JAPAN	3
B	ALGERIA	25

TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)
17025	see document last year
17043	see document last year

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
LSDV pan capripox PCR, LSDV DIVA PCR, LSDV isolation , LSDV ELISA	BELAC

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

approval for contained use for work with capripox viruses under BSL3 conditions; leefmilieu Brussels

TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOA?H?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOA?H?

Yes

Title of event	Date	location	Role (speaker, presenting poster, short communications)	Title of the work presented
GFTAD SGE LSDV	2025-03-04	online	speaker	Latest activities on LSDV and update on diagnosis
GFTAD meeting on PPR and LSDV	2025-07-02	online	speaker	LSDV outbreak in Europe – Information LSDV strains in Europe
WOAH regional workshop on LSD and other TADs control in Asia and the Pacific	2025-07-06	Manila, Philippines	speaker	LSDV diagnosis and surveillance ; research activities at the EURL for LSDV
GFTAD 1st conference on TADs in Europe	2025-09-22	Belgrade, Serbia	speaker	Lumpy skin disease: update from the EU/WOAH reference laboratory
REMESA meeting	2025-12-16	Valletta, Malta	speaker	Lumpy skin disease virus: strains and control measures

TOR10: NETWORK WITH WOA?H REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOA?H Reference Laboratories designated for the same pathogen or disease?

Nick De Regge - -

Yes

24. Are you a member of a network of WOA Reference Laboratories designated for the same pathogen?

No

25. Did you organise or participate in inter-laboratory proficiency tests with WOA Reference Laboratories designated for the same pathogen during the past 2 years?

Yes

Purpose of the proficiency test:	Role of your Reference Laboratory (organiser/ participant)	No. participating Laboratories	Participating WOA Ref. Labs/ organising WOA Ref Lab
evaluation PCR LSDV	participant	4	organize: OVI south Africa

26. Did your laboratory collaborate with other WOA Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOA Reference Laboratories for the same pathogen during the past 2 years?

Yes

Purpose for inter-laboratory test comparisons ¹	Role of your reference laboratory (organizer/participant)	No. participating laboratories	Name of the test	WOAH Member Countries
LSDV serology and virology	organizer; PT for European NRL and third countries	55	LSDV ELISA; LSDV PCR	
LSDV serology and virology	organizer	1	LSDV ELISA, LSDV VNT, LSDV PCR	INDIA,
LSDV serology and virology	organizer; PT for South-East Asian countries	4	LSDV ELISA, LSDV PCR	

TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOA?

Yes

Kind of consultancy	Location	Subject (facultative)
responding to technical queries from WOA	online	information code chapter free status; information about biological vector transmission of LSDV; information about LSDV in milk
review of WOA standards	online	duration to obtain LSDV free status

29. Additional comments regarding your report: